Stay updated on Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.

Latest updates to the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe study record now presents detailed information about the entinostat and pembrolizumab lymphoma trial, including its design, participant criteria, treatment arms, outcomes, and locations. It also shows the study as active but not recruiting.SummaryDifference50%

- Check21 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA notice appears announcing NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It is shown above the study page’s 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content with a generic error page. This indicates that access to the NCT03179930 study record is blocked, with the error text visible on the page.SummaryDifference18%

Stay in the know with updates to Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.